Pneumococcal Vaccination for Adults ≥65 Years
Adults aged 65 years and older should receive a single dose of PCV21, PCV20, or PCV15 (followed by PPSV23 if PCV15 is chosen), with the choice depending on prior vaccination history and local serotype epidemiology. 1
Vaccine Options and Selection
The 2024 ACIP guidelines provide three acceptable pneumococcal conjugate vaccine options for adults ≥65 years:
- PCV21 (CAPVAXIVE) - single dose
- PCV20 (Prevnar20) - single dose
- PCV15 (VAXNEUVANCE) - single dose followed by PPSV23 ≥1 year later
All three options are considered equivalent for vaccine-naïve adults, though PCV21 and PCV20 offer the advantage of single-dose completion compared to the two-dose PCV15/PPSV23 series. 1
Vaccination Algorithm Based on Prior History
Never Vaccinated or PCV7 Only
Administer a single dose of PCV21, PCV20, or PCV15. If PCV15 is selected, give PPSV23 ≥1 year later (minimum 8 weeks for immunocompromised patients, those with cochlear implants, or CSF leaks). 1
PPSV23 Only Previously
Administer PCV21, PCV20, or PCV15 ≥1 year after the last PPSV23 dose. 1
PCV13 Only Previously
Administer PCV21, PCV20, or PPSV23 ≥1 year after PCV13 (≥8 weeks for high-risk patients). 1
PCV13 + PPSV23 Before Age 65
Administer PCV21, PCV20, or PPSV23. If using PCV21/PCV20, wait ≥5 years after the last pneumococcal vaccine. If using PPSV23, wait ≥1 year after PCV13 and ≥5 years after prior PPSV23. 1
PCV13 + PPSV23 at Age ≥65 (Series Complete)
Shared clinical decision-making is recommended regarding whether to administer PCV21 or PCV20. If given, wait ≥5 years after the last pneumococcal vaccine dose. 1
Important Considerations
Serotype 4 Prevalence
Critical caveat: In populations where ≥30% of pneumococcal disease is caused by serotype 4, PCV20 or the PCV15/PPSV23 series are preferred over PCV21, as PCV21 does not include serotype 4. These vaccines provide broader coverage against locally circulating strains in such settings. 1
Practical Implementation
The single-dose PCV20 or PCV21 strategies offer superior feasibility compared to the two-dose PCV15/PPSV23 series, which requires patients to return 1 year later. This is particularly relevant for underserved populations where follow-up may be challenging. 2
Coadministration
Pneumococcal vaccines can be administered simultaneously with other age-appropriate vaccines (e.g., influenza, COVID-19, shingles) at the same visit, provided no specific contraindications exist. 1
Evidence Quality
The 2024 ACIP recommendations 1 represent the most current authoritative guidance, superseding the 2023 recommendations 3. The addition of PCV21 as an option reflects its recent FDA approval and comparable immunogenicity to PCV20 for shared serotypes, with superior responses for its unique serotypes. 4
The choice between PCV20 and PCV21 should be guided by local serotype epidemiology data, as their relative effectiveness varies by geographic region and time period based on circulating pneumococcal strains. 4, 5